# FORM 10

## NOTICE OF PROPOSED SIGNIFICANT TRANSACTION (not involving an issuance or potential issuance of a listed security)[1]

Name of Listed Issuer: TempraMed Technologies Ltd. (the “Issuer”).

Trading Symbol: VIVI

Issued and Outstanding Securities of the Issuer Prior to Transaction: 78,580,705

Date of News Release Fully Disclosing the Transaction: June 4, 2026

### 1. Transaction

1. Provide details of the transaction including the date, description and location of assets, if applicable, parties to and type of agreement (eg: sale, option, license, contract for Investor Relations Activities etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: _____

The Issuer has engaged Plutus Invest & Consulting GmbH (“Plutus”) (Principal: Marco Messina, address: Buchtstrasse 13, Bremen 28195, Germany, Phone: +49 421 1754 0174, email: contact@plutuinves.de) to provide certain marketing services in connection with the Company’s listing on the Frankfurt Stock Exchange for a period of twelve (12) months, commencing on June 1, 2026. This arm’s length Agreement will provide the Company with marketing services that include, among others, the information distribution, media distribution, IR management etc. with an objective to generally bring attention to the business of the Company to the German market (“the Program”).

The Company has agreed to pay Plutus a total fee of €100,000 (approximately CAD $160,000), which will be paid in advance for the entirety of the program. To the knowledge of the Company, at the time of entering into the agreement, Plutus and its principals, directly or indirectly, do not own any common shares or other securities of the Company

2. Provide the following information in relation to the total consideration for the transaction (including details of all cash, non-convertible debt securities or other consideration) and any required work commitments:

[1] If the transaction involved the issuance of securities, other than debt securities that are not convertible into listed securities, use Form 9.

(a) Total aggregate consideration in Canadian dollars: €100,000 (approximately CAD $160,000)

(b) Cash: €100,000 (approximately CAD $160,000) .

(c) Other: ______ .

(d) Work commitments: ______ .

3. State how the purchase or sale price and the terms of any agreement were determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc). arm's-length negotiation

4. Provide details of any appraisal or valuation of the subject of the transaction known to management of the Issuer: Not Applicable ______ .

5. If the transaction is an acquisition, details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: Not Applicable ______ .

6. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the transaction (including warrants, options, etc.):

(a) Details of any dealer, agent, broker or other person receiving compensation in connection with the transaction (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): Not Applicable ______.

(b) Cash ______ .

(c) Other ______ .

7. State whether the vendor, sales agent, broker or other person receiving compensation in connection with the transaction is a Related Person or has any other relationship with the Issuer and provide details of the relationship. The Vendor is arm's length to the Company ______

8. If applicable, indicate whether the transaction is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. Not Applicable_______________________________________
_____________________________________________________________
_____________________________________________________________ .

## 2. Development

Provide details of the development. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: _____________________________________________________
_____________________________________________________________
_____________________________________________________________

## 3. Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. To the knowledge of the Issuer, at the time an agreement in principle was reached, no party to the transaction had knowledge of any undisclosed material information relating to the Issuer, other than in relation to the transaction.

3. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

4. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

5. All of the information in this Form 10 Notice of Proposed Significant Transaction is true.

Dated June 4, 2026.

Gabriel Kabazo
Name of Director or Senior Officer

/S/ "*Gabriel Kabazo*"
Signature

CFO
Official Capacity